Total Tau (T Tau) In Cerebrospinal Fluid is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Total tau (t-tau) in cerebrospinal fluid (CSF) is a core biomarker for neurodegeneration that reflects neuronal damage and axonal injury. It is one of the three CSF biomarkers in the ATN (Amyloid-Tau-Neurodegeneration) framework for Alzheimer's disease diagnosis.
Tau is a microtubule-associated protein primarily expressed in neurons. When neurons are damaged or degenerate, tau is released into the CSF where it can be measured as total tau (both phosphorylated and unphosphorylated forms).[1]
Unlike phosphorylated tau (p-tau) which is specific to Alzheimer's disease pathology, total tau is a non-specific marker of neuronal injury that can be elevated in various neurological conditions.
In Alzheimer's disease:
Total tau is the "T" (tau) and "N" (neurodegeneration) marker in the ATN classification:
| ATN Marker | What it Measures | AD-Specific? |
|---|---|---|
| A (Amyloid) | Aβ42/40 ratio, amyloid PET | Yes |
| T (Tau) | p-tau 181/217/231 | Yes |
| N (Neurodegeneration) | t-tau, NfL, MRI | No |
Elevated CSF t-tau helps distinguish AD from:
| Condition | t-tau Level |
|---|---|
| Alzheimer's Disease | Markedly elevated |
| Frontotemporal Dementia | Mildly elevated |
| Dementia with Lewy Bodies | Mildly elevated |
| Normal Aging | Normal |
| Psychiatric disorders | Normal |
Elevated t-tau is seen in:
| t-tau Level | Interpretation |
|---|---|
| <300 pg/mL | Normal |
| 300-500 pg/mL | Borderline |
| >500 pg/mL | Elevated - suggests neurodegeneration |
| >1000 pg/mL | Highly elevated - consider CJD |
Note: Values vary by laboratory and assay kit.
Best diagnostic performance when combined with:
| Biomarker | Specificity | Reflects | Clinical Use |
|---|---|---|---|
| t-tau | Non-specific | Neuronal damage | Neurodegeneration marker |
| p-tau 181 | AD-specific | Tau pathology | AD diagnosis |
| p-tau 217 | AD-specific | Tau pathology | Early AD detection |
| p-tau 231 | AD-specific | Early tau pathology | Preclinical AD |
| NfL | Non-specific | Axonal injury | General neurodegeneration |
The study of Total Tau (T Tau) In Cerebrospinal Fluid has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Blennow, K., & Hampel, H. (2003). CSF markers for incipient Alzheimer's disease. The Lancet Neurology, 2(10), 605-613.
[2] Olsson, B., et al. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology, 15(7), 673-684.
[3] Buchanan, C. R., et al. (2023). The effect of aging on tau pathology and its relationship to cognitive decline. Brain, 146(7), 2849-2861.